Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Seeks Input to Gird for Summer Outbreaks, FPMAJ Ready to Ask for Ramp-Up
July 23, 2024
- Japan’s Fall-Winter COVID Vaccinations Likely to Start from October
July 23, 2024
- MHLW Panel to Review Takeda’s Fruzaqla on Aug. 2; Truvada, Keytruda, Prevenar 20 on Roster Too
July 22, 2024
- MHLW Sets Exceptions to All-Case PMS through Revised Q&A
July 22, 2024
- Japan Panel Says No to Full Approval of HeartSheet, Clears Breyanzi’s Broader Label
July 22, 2024
- Japan Panel Discusses Details of NIP for Shingles Jabs, OKs Inclusion of Prevenar 20
July 19, 2024
- Lilly’s Alzheimer’s Med Up for Health Ministry Panel Review on August 1
July 19, 2024
- MHLW Pharma Management Director Hints at Addressing “Zero” Premium Issue
July 19, 2024
- Chuikyo OKs Plan for Drug Price Survey in FY2024
July 18, 2024
- Debates on FY2025 Off-Year Price Revision Officially Set Sail at Chuikyo
July 18, 2024
- Label Revisions Ordered for Opdivo, Yervoy, Duvroq, and More
July 18, 2024
- LDP Lawmakers Call for Expanded Budget for Pharma Innovation, Stable Supplies
July 18, 2024
- MHLW Clarifies Criteria for “Medical Necessity” of LLPs before Elective Care Rollout
July 17, 2024
- Pharma Innovation, Supply Raised as Key Topics for FY2025 Budget: LDP Confab
July 10, 2024
- Japan Wants to Spur Regulatory Use of RWD, but Still Puts Weight on RCTs
July 10, 2024
- Ex-Health Minister Otsuji to Retire from Politics Next Summer
July 10, 2024
- PMDA to Push Simultaneous Development of Pediatric Drugs via New Consultation Center
July 9, 2024
- LDP Group Renews Call for Gender-Neutral HPV Vaccination
July 9, 2024
- MHLW Proposes New Scheme for Development Requests to Fight Drug Loss
July 8, 2024
- Breyanzi’s Label Expansion Up for MHLW Panel Review on July 19
July 8, 2024
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…